Genetics of susceptibility to pristane-induced plasmacytomas in BALB/cAn: reduced susceptibility in BALB/cJ with a brief description of pristane-induced arthritis.
Open Access
- 1 October 1981
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 127 (4) , 1591-1595
- https://doi.org/10.4049/jimmunol.127.4.1591
Abstract
BALB/cAn and BALB/cJ inbred strains of mice were separated 43 yr ago, but are still very closely related because they carry the same allelomorphs at many loci. When injected 3 times i.p. with 0.5 ml of pristane (2, 6, 10, 14 tetramethylpentadecane) 11% of strain BALB/cJ develop plasmacytomas in contrast to 61% in BALB/cAn sublines. BALB/cJ first injected with pristane as neonates also developed a reduced number of plasmacytomas as compared with BALB/cAn. About 20% of pristane-treated BALB/cAn and 70% of pristane-treated BALB/cJ develop arthritis, which first appeared in the ankle joints after a latent period of 4 mo or more.This publication has 3 references indexed in Scilit:
- Avian leukosis virus-induced tumors have common proviral integration sites and synthesize discrete new RNAs: oncogenesis by promoter insertionCell, 1981
- The genetic behaviour of a cloned mouse ribosomal DNA segment mimics mouse ribosomal gene evolutionJournal of Molecular Biology, 1979
- Genetic control of alpha-fetoprotein synthesis in the mouse.The Journal of Experimental Medicine, 1977